Skip to main content
FENC logo

Fennec Pharmaceuticals Inc.

FENCNASDAQHealthcareBiotechnology

$10.15Today:- (-)1Y +15.18%

As of Oct 26, 2026 close

Market cap
$369.76M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.65$13.25
Volume (live)
-
Avg. volume (3M)
122.90K

Fennec Pharmaceuticals (FENC) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Fennec Pharmaceuticals used $12.47M of cash in operating activities. Free cash flow was −$12.47M.

Fennec Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Fennec Pharmaceuticals Inc. (FENC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-9.74-0.44-16.05-23.71-17.35-18.11-12.78-9.89-7.05
Depreciation & Amortization0.100.800.290.150.020.000.000.000.00
Stock Based Compensation7.035.065.354.093.752.882.671.831.52
Change in Working Capital-12.0416.94-8.171.10-0.93-0.660.570.131.01
Change in Accounts Receivable-12.44-7.87-7.27-1.550.000.000.000.000.00
Change in Inventory-1.280.58-1.58-0.580.000.000.000.000.00
Change in Accounts Payable1.39-0.540.001.61-0.79-0.040.580.180.61
Change in Other Working Capital-4.720.290.680.280.28-0.62-0.01-0.050.40
Other Operating Activities5.075.411.430.280.280.390.480.110.88
Net Cash from Operating Activities-12.4726.98-17.14-18.06-14.22-15.60-9.06-7.83-3.64
Investing Activities
Net Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Financing Activities
Debt Repayment-19.48-13.005.00-5.005.000.000.000.000.00
Common Stock Issued44.241.300.000.930.0332.430.002.2127.38
Common Stock Repurchased0.00-0.18-0.08-0.190.000.000.000.000.00
Other Financing Activities-1.95-1.741.72-0.13-0.06-0.14-0.072.350.59
Net Cash from Financing Activities22.63-13.626.6420.734.9832.29-0.072.3527.98
Summary
Net Change in Cash10.1513.37-10.512.67-9.2416.69-9.13-5.4824.33
Cash at Beginning of Period26.6313.2723.7721.1030.3413.6522.7828.263.93
Cash at End of Period36.7926.6313.2723.7721.1030.3413.6522.7828.26
Free Cash Flow-12.4726.98-17.14-18.06-14.22-15.60-9.06-7.83-3.64

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Fennec Pharmaceuticals Cash Flow

What is Fennec Pharmaceuticals's free cash flow?

Fennec Pharmaceuticals had negative free cash flow of $12.47M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Fennec Pharmaceuticals pay dividends or buy back shares?

Fennec Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition